Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Cottu

Showing results (51-60 of 140) with videos related to

Pageof 14
Sort By:
British Journal of Clinical Pharmacology|February 25, 2024
Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approachAlexandre Acramel, Sandy Blondeel-Gomes, Mathilde Dupré, et al.
ESMO Open|September 27, 2019
UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)Ines Vaz-Luis, Paul Cottu, Christel Mesleard, et al.
Breast (Edinburgh, Scotland)|April 8, 2026
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practiceHope S Rugo, Adam Brufsky, Rachel M Layman, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2010
Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinomaNadège Gruel, Carlo Lucchesi, Virginie Raynal, et al.
Oncotarget|September 8, 2016
ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomasGabrielle Deniziaut, Jean Christophe Tille, François-Clément Bidard, et al.
Bulletin Du Cancer|April 30, 2011
[Concurrent whole-brain radiotherapy with trastuzumab for treatment of brain metastases in breast cancer patients: questions and answers]Hind Riahi Idrissi, Cyrus Chargari, Marc A Bollet, et al.
JMIR Research Protocols|January 12, 2022
Helping Patients Communicate With Oncologists When Cancer Treatment Resistance Occurs to Develop, Test, and Implement a Patient Communication Aid: Sequential Collaborative Mixed Methods StudyAnne Brédart, Aude Rault, Johanna Terrasson, et al.
International Journal of Cancer|November 28, 2008
Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotypePatricia de Cremoux, Anne de la Rochefordière, Alexia Savignoni, et al.
BMJ Supportive & Palliative Care|April 30, 2021
Advanced cancer and COVID-19 comorbidity: medical oncology-palliative medicine ethics meetings in a comprehensive cancer centreLaura Thery, Pauline Vaflard, Perrine Vuagnat, et al.
British Journal of Cancer|January 21, 2021
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trialLuc Cabel, Frédérique Berger, Paul Cottu, et al.
Pageof 14

Showing results (51-60 of 140) with videos related to

Sort By:
Pageof 14
British Journal of Clinical Pharmacology|February 25, 2024
Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approachAlexandre Acramel, Sandy Blondeel-Gomes, Mathilde Dupré, et al.
ESMO Open|September 27, 2019
UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)Ines Vaz-Luis, Paul Cottu, Christel Mesleard, et al.
Breast (Edinburgh, Scotland)|April 8, 2026
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practiceHope S Rugo, Adam Brufsky, Rachel M Layman, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2010
Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinomaNadège Gruel, Carlo Lucchesi, Virginie Raynal, et al.
Oncotarget|September 8, 2016
ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomasGabrielle Deniziaut, Jean Christophe Tille, François-Clément Bidard, et al.
Bulletin Du Cancer|April 30, 2011
[Concurrent whole-brain radiotherapy with trastuzumab for treatment of brain metastases in breast cancer patients: questions and answers]Hind Riahi Idrissi, Cyrus Chargari, Marc A Bollet, et al.
JMIR Research Protocols|January 12, 2022
Helping Patients Communicate With Oncologists When Cancer Treatment Resistance Occurs to Develop, Test, and Implement a Patient Communication Aid: Sequential Collaborative Mixed Methods StudyAnne Brédart, Aude Rault, Johanna Terrasson, et al.
International Journal of Cancer|November 28, 2008
Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotypePatricia de Cremoux, Anne de la Rochefordière, Alexia Savignoni, et al.
BMJ Supportive & Palliative Care|April 30, 2021
Advanced cancer and COVID-19 comorbidity: medical oncology-palliative medicine ethics meetings in a comprehensive cancer centreLaura Thery, Pauline Vaflard, Perrine Vuagnat, et al.
British Journal of Cancer|January 21, 2021
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trialLuc Cabel, Frédérique Berger, Paul Cottu, et al.
Pageof 14